Trandolapril demonstrates significantly greater potency in lowering blood pressure and inhibiting ACE activity compared to enalapril in vivo, which is attributed to its higher lipophilicity and the intrinsic ACE inhibitory activity of the prodrug itself.
No takes yet. Share an insight, caveat, or question.
Preclinical potency differences should not alter human prescribing; leaves open need for comparative clinical trials.
Chevillard et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: